Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type2 W6 M! O( E% n* B4 o4 ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
3 z0 ~3 L' u3 H8 Z+ Author Affiliations
$ a k: s$ ]* F
' l2 U, t- b% `+ p1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
6 _. P$ M) ~; k U7 z( k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
`- e3 ?% K+ U: ]# k0 V8 K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ z: r, E+ A3 m/ ~ j4 ?4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
; I$ E8 f& K* x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
1 Z% a* b9 }5 L* [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ! r& T( T+ n1 ?2 {
7Kinki University School of Medicine, Osaka 589-8511, Japan 1 \* _- }3 g7 Y1 y& g$ {
8Izumi Municipal Hospital, Osaka 594-0071, Japan
, j6 n, P2 O) k' J q9 G9 b9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
|( C5 @: D" D; Z7 PCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp + O9 q5 J& B! G# V
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , t4 [. M" l4 n* x, Q, L- Q
% y+ L H4 h8 r0 o! E
|